Leptomeningeal Disease Pipeline

DelveInsight’s, “Leptomeningeal Disease - Pipeline Insight, 2025,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Leptomeningeal Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Leptomeningeal Disease Understanding

Leptomeningeal Disease: Overview

Leptomeningeal disease (LMD) is a late-stage complication of systemic cancers caused by multifocal metastases to the leptomeninges, which consist of the pia mater, arachnoid, and subarachnoid space. Leptomeningeal disease occurs when cancer cells migrate from your breast, lung, or some other part of your body to your cerebrospinal fluid (CSF). This liquid circulates nutrients and chemicals to the brain and spinal cord. This condition neoplastic meningitis, carcinomatous meningitis, lymphomatous meningitis, and leukemic meningitis. LMD also known as Leptomeningeal carcinomatosis (LMC), leptomeningeal metastasis, is the metastatic spread of cancer to the pia mater, arachnoid, and subarachnoid space. LMD typically presents with non-specific neurological signs and symptoms that tend to progress insidiously over time. On imaging, patients may present with focal sites of enhancing disease or a more diffuse pattern with the entire neuraxis at potential risk. As result, the presenting symptoms may be findings are usually attributable to dysfunction of the cranial nerves, cerebellum, spine, or increased intracranial pressure. Some common symptoms of the disease include headache, altered mentation, nausea, and vomiting, as well as symptoms related to radiculopathies, myelopathies, and cauda equina syndrome. It is an uncommon condition that occurs in about 5% of cancer patients. Diagnosing of the LMD often involves taking a magnetic resonance imaging (MRI) scan of the brain and spinal cord, as well as a evaluating a sample of cerebrospinal fluid, which can be obtained through a minimally invasive lumbar puncture procedure. Unfortunately, LMD remains incurable, so treatments are often symptom directed. However, for some cancers, new therapies have improved prognoses dramatically. The treatment for LMD is based on 2 guiding principles: to reduce pressure on the brain caused by any CSF buildup, and to reduce the number of cancer cells causing the pressure. The treatment options for LMD includes oral targeted therapies that can cross the blood - brain barrier and may be used to treat LMD. Other drugs may be administered directly into the CSF through a special port placed into the brain by a neurosurgeon. Radiation therapy can also be used to kill cancer cells on the leptomeninges.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Leptomeningeal Disease R&D. The therapies under development are focused on novel approaches for Leptomeningeal Disease.

Leptomeningeal Disease Emerging Drugs Chapters

This segment of the Leptomeningeal Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Leptomeningeal Disease Emerging Drugs

 

ANG1005: Angiochem Inc

ANG1005 is a novel targeted taxane derivative that is the first oncology product to leverage Angiochem’s technology platform to cross the blood-brain barrier (BBB) and enter cancer cells.  ANG1005 is an Angiopep-2 paclitaxel conjugate that gains entry into the brain by targeting the LRP-1, which is one of the most highly-expressed receptors on the surface of the BBB.  Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain. The drug is in Phase III for the treatment of leptomeningeal disease from breast cancer. 

 

Paxalisib: Kazia Therapeutics

Paxalisib (formerly GDC-0084), a small molecule inhibitor of the PI3K / AKT / mTOR pathway invented by Genentech, Inc. Kazia entered into a worldwide exclusive license agreement with Genentech in October 2016. Currently, the Phase I study evaluates the GDC-0084, in combination with radiation therapy in people who have solid tumor brain metastases or leptomeningeal metastases.

Further product details are provided in the report……..

Leptomeningeal Disease : Therapeutic Assessment

This segment of the report provides insights about the different Leptomeningeal Disease  drugs segregated based on following parameters that define the scope of the report, such as:

 

Major Players in Leptomeningeal Disease 

There are approx. 7+ key companies which are developing the therapies for Leptomeningeal Disease . The companies which have their Leptomeningeal Disease  drug candidates in the most advanced stage, i.e. phase III include, Angiochem Inc.

 

Phases

DelveInsight’s report covers around 7+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Leptomeningeal Disease  pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Intra-articular
• Intraocular
• Intrathecal 
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Leptomeningeal Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Leptomeningeal Disease therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Leptomeningeal Disease drugs.

Leptomeningeal Disease Report Insights

• Leptomeningeal Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Leptomeningeal Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Leptomeningeal Disease drugs?
• How many Leptomeningeal Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Leptomeningeal Disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Leptomeningeal Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Leptomeningeal Disease and their status?
• What are the key designations that have been granted to the emerging drugs?